X0202 SCHEDULE 13G/A 0001104659-25-014402 0001940272 XXXXXXXX LIVE 3 Common Stock, $0.001 par value 03/31/2026 0001750149 Inhibikase Therapeutics, Inc. 45719W205 1000 N. West Street Suite 1200 Wilmington DE 19801 Rule 13d-1(b) ADAR1 Capital Management, LLC b TX 0.00 13860028.00 0.00 13860028.00 13860028.00 N 9.9 IA OO Includes (i) 4,786,694 shares of common stock, par value $0.001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 694,329 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC, (iii) 510,949 shares of Common Stock held by ADAR1 SPV I, LP, (iv) 614,600 shares of Common Stock held by other separately managed accounts and (v) 7,253,456 shares of Common Stock underlying milestone warrants held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP as of March 31, 2026. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP; Spearhead Insurance Solutions IDF, LLC; ADAR1 SPV I, LP and the separately managed accounts. Based on 132,032,636 shares of Common Stock of Inhibikase Therapeutics, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 12, 2026. ADAR1 Capital Management GP, LLC b TX 0.00 11832998.00 0.00 11832998.00 11832998.00 N 8.5 OO Includes (i) 4,786,694 shares of common stock, par value $0.001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 510,949 shares of Common Stock held by ADAR1 SPV I, LP and (iii) 6,535,355 shares of Common Stock underlying milestone warrants held by ADAR1 Partners, LP and ADAR1 SPV I, LP as of March 31, 2026. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. Based on 132,032,636 shares of Common Stock of Inhibikase Therapeutics, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 12, 2026. Daniel Schneeberger b V8 0.00 13860028.00 0.00 13860028.00 13860028.00 N 9.9 HC IN Includes (i) 4,786,694 shares of common stock, par value $0.001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 694,329 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC, (iii) 510,949 shares of Common Stock held by ADAR1 SPV I, LP, (iv) 614,600 shares of Common Stock held by other separately managed accounts and (v) 7,253,456 shares of Common Stock underlying milestone warrants held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP as of March 31, 2026. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP; Spearhead Insurance Solutions IDF, LLC; ADAR1 SPV I, LP and the separately managed accounts referenced above. Based on 132,032,636 shares of Common Stock of Inhibikase Therapeutics, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 12, 2026. Inhibikase Therapeutics, Inc. 1000 N. West Street, Suite 1200 Wilmington, DE 19801 This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); (ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and (iii) Daniel Schneeberger ("Mr. Schneeberger"). The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738. (i) ADAR1 Capital Management is a Texas limited liability company; (ii) ADAR1 General Partner is a Texas limited liability company; and (iii) Mr. Schneeberger is a citizen of Switzerland. N IA HC The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. Y Y N Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E). Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. ADAR1 Capital Management, LLC /s/ Daniel Schneeberger 05/15/2026 ADAR1 Capital Management GP, LLC /s/ Daniel Schneeberger 05/15/2026 Daniel Schneeberger /s/ Daniel Schneeberger 05/15/2026